3.4409194136642E-05 0.000172045970683406 6.88183882732841E-05 -0.000309682747229974 0.00306241827816388 0.00344091941366733 0.00285596311334383 0.00178927809510695
Sign Up Today X
Thanks for submitting the form.
Stockreport

Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise? [Yahoo! Finance]

Gilead Sciences, Inc. (GILD)  More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Gilead Sciences, Inc. 's GILD Cell Therapy franchise currently comprises Yescarta and Tecartus. Sales from this unit decreased 7% year over year to $1.8 billion (in 2025) due to ongoing competitive headwinds. Yescarta sales decreased 5% year over year to $1.5 billion, primarily as a result of in- and out-of-class competition. Tecartus sales decreased 15% to $344 million due to in-class competition. GILD anticipates competitive pressure in cell therapies' business to continue in 2026, including new market entrants in several countries outside the United States. In a move to combat this decline, Gilead recently announced that it will acquire a clinical-stage biotechnology company, Arcellx ACLX, for $115 per share in cash plus a $5 contingent value right, implying an equity value of $7.8 billion. Gilead's subsidiary, Kite, already has a collaboration to co-develop and co-commercialize Arcellx's lead pipeline candidate, anitocabtagene autoleucel (anito-cel). A biologics licen [Read more]
IMPACT SNAPSHOT EVENT TIME: GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
GILD alerts
from News Quantified
GILD
NEWS
GILD
Earnings
GILD
Analyst Actions
GILD
SEC Filings
Stockreport

Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise? [Yahoo! Finance]

Gilead Sciences, Inc.  (GILD) 
More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Gilead Sciences, Inc. 's GILD Cell Therapy franchise currently comprises Yescarta and Tecartus. Sales from this unit decreased 7% year over year to $1.8 billion (in 2025) due to ongoing competitive headwinds. Yescarta sales decreased 5% year over year to $1.5 billion, primarily as a result of in- and out-of-class competition. Tecartus sales decreased 15% to $344 million due to in-class competition. GILD anticipates competitive pressure in cell therapies' business to continue in 2026, including new market entrants in several countries outside the United States. In a move to combat this decline, Gilead recently announced that it will acquire a clinical-stage biotechnology company, Arcellx ACLX, for $115 per share in cash plus a $5 contingent value right, implying an equity value of $7.8 billion. Gilead's subsidiary, Kite, already has a collaboration to co-develop and co-commercialize Arcellx's lead pipeline candidate, anitocabtagene autoleucel (anito-cel). A biologics licen [Read more]
IMPACT SNAPSHOT
EVENT TIME:
GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS